8月22日，天境生物(IMAB)开盘上涨5.94%，截至21:30，报4.99美元/股，成交21.41万美元，总市值5.74 亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 本文源自：金融界 作者：行情君 ...

Core Viewpoint - Tianjing Bio (IMAB) has shown significant growth in revenue and is preparing to release its fiscal year 2024 mid-term report, indicating a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients globally [1].

Core Viewpoint - I-Mab is actively participating in investor conferences in September 2025 to engage with potential investors and showcase its innovative pipeline in precision immuno-oncology for cancer treatment [1][2]. Group 1: Conference Participation - I-Mab's management team will attend the Cantor Global Healthcare Conference from September 3-5, 2025, focusing on one-on-one meetings [1]. - The company will also present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:30 AM ET, which will include a company presentation and one-on-one meetings [2]. Group 2: Company Overview - I-Mab is a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment [3]. - The company's leading product candidate, givastomig, is a bispecific antibody targeting Claudin 18.2, designed for treating Claudin 18.2-positive gastric cancers [3]. - Givastomig is currently in Phase 1 trials, demonstrating strong tumor-binding and anti-tumor activity while minimizing common toxicities associated with other 4-1BB agents [3].

本文源自：金融界 作者：行情君 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 8月20日，天境生物(IMAB)开盘上涨10.2%，截至21:32，报4.64美元/股，成交56.44万美元，总市值5.34 亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 ...

Exhibit 99.1 I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update ROCKVILLE, MD, August 20, 2025 – I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progress and business updates. "The first half of 2025 has been transformative for I-Mab," sai ...

Core Insights - I-Mab has reported transformative progress in the first half of 2025, particularly with the promising Phase 1b combination data for its drug givastomig, which targets Claudin 18.2 for metastatic gastric cancers [2][3] Financial Performance - For the three months ended June 30, 2025, the company reported a net loss of $5.5 million, compared to a net loss of $8.9 million for the same period in 2024 [16] - For the six months ended June 30, 2025, the net loss was $8.7 million, an improvement from a net loss of $18.4 million in the same period in 2024 [16] - Research and development expenses decreased to $3.3 million for the three months ended June 30, 2025, down from $5.2 million in 2024 [10] - Administrative expenses also decreased to $3.8 million for the three months ended June 30, 2025, compared to $11.9 million in 2024 [11] Cash Position - As of June 30, 2025, I-Mab had cash and cash equivalents of $165.6 million, which is expected to fund operations through the fourth quarter of 2028 [7][6] - The company raised approximately $61.2 million from an underwritten offering in August 2025, strengthening its balance sheet [6] Clinical Developments - Givastomig demonstrated an 83% objective response rate in a Phase 1b study when combined with immunochemotherapy, with topline data expected in Q1 2026 [3][6] - The company has completed enrollment for the Phase 1b dose expansion study of givastomig in combination with nivolumab and mFOLFOX6 for first-line metastatic gastric cancers [3] Upcoming Milestones - I-Mab anticipates updates in 2026 for other programs, including ragistomig and uliledlimab, which are under development by ABL Bio and TJ Biopharma, respectively [4] Shareholder Information - As of June 30, 2025, the company had 188,108,178 ordinary shares outstanding, which will increase to 264,774,837 shares post-offering [8][9]

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

8月18日，天境生物(IMAB)开盘上涨2.57%，截至21:30，报4.995美元/股，成交47.05万美元，总市值 5.74亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 本文源自：金融界 作者：行情君 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 ...

8月15日，天境生物(IMAB)盘中上涨11.01%，截至21:44，报5.728美元/股，成交579.98万美元，总市值 6.59亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 大事提醒： 本文源自：金融界 作者：行情君 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 ...

Core Viewpoint - Tianjing Bio (IMAB) is focused on developing innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases, aiming to fill clinical treatment gaps and improve patient survival globally [1]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 interim report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals that address unmet clinical needs and significantly enhance the quality of life for patients worldwide [1].